2023 Established Investigator Awardee Explores Ways to Measure Changes in Patients Skin Over Time
Project Summary Provided by: Andreea Bujor, MD, PhD
Last year, our research team was awarded a grant to study Spatial Frequency Domain Imaging (SFDI) as a new method to quantify skin changes in scleroderma. One of the major challenges in managing scleroderma is accurately assessing and monitoring the skin changes associated with the
disease. Traditional methods, such as skin scoring and biopsies, can be subjective or invasive, underscoring the need for more objective and patient-
friendly approaches. SFDI is an advanced imaging technique that uses specialized light patterns to capture detailed information about the skin’s
structure, composition, and underlying physiological processes.

Our key findings from year one of this study are:
You can learn more about our project on the Foundation’s YouTube channel at Meet a scleroderma investigator: Andreea Monica Bujor, M.D., Ph.D.
Through the support of the National Scleroderma Foundation, our research team has made exciting progress in evaluating the potential of this imaging
technology for accurate and non-invasive assessment of skin involvement in people living with scleroderma.
- SFDI can accurately detect longitudinal changes in the skin of individual scleroderma patients over time. Remarkably, the changes in SFDI parameters correlated with changes in the modified Rodnan Skin Score (mRSS), a widely used measure of skin involvement in scleroderma.
- SFDI parameters significantly correlate with dermal thickness measured by ultrasound. This finding further validates the utility of SFDI in monitoring skin changes in scleroderma patients.
These results are groundbreaking, as they demonstrate for the first time that SFDI can not only detect skin changes in scleroderma patients, but also can
track these changes over time in individual patients. Additionally, the correlation with ultrasound-measured dermal thickness provides further evidence of SFDI’s accuracy and reliability. By leveraging SFDI, we aim to develop a non-invasive, objective, and quantitative tool for monitoring skin involvement in scleroderma patients. This could enable more personalized treatment plans, improved disease management, and better long-term outcomes for patients.
I would like to express my sincere gratitude for the opportunity to collaborate with the National Scleroderma Foundation. The support and resources
provided by the Foundation have been invaluable in advancing our research goals. Throughout the partnership, I have been consistently impressed by the Foundation’s unwavering commitment to improving the lives of individuals affected by scleroderma. The dedication and passion of the team have been truly inspiring, and it has been a privilege to work alongside such caring professionals.
Receiving this grant has had a profound impact on our research goals and future plans. It has provided us with the necessary resources to delve deeper into the potential of spatial frequency domain imaging for accurate and non-invasive assessment of skin involvement in scleroderma patients. The funding has allowed us to expand our study cohort, enabling more comprehensive data collection and analysis. The data and insights gained from this research could pave the way for improved diagnostic and monitoring tools, ultimately leading to better patient outcomes and quality of life for those affected by scleroderma. We are excited about the possibilities that lie ahead and are committed to translating our findings into meaningful clinical applications.
You can support the Foundation’s efforts to advance medical research now by making a donation at scleroderma.org/supportresearch.